Rhinomed Limited Stock Market Press Releases and Company Profile
UK Pharmacy Distribution Secured for Mute
UK Pharmacy Distribution Secured for Mute

Melbourne, Aug 21, 2015 AEST (ABN Newswire) - Australian respiratory technology company Rhinomed Ltd (googlechartASX:RNO), is pleased to announce its Mute snoring and sleep technology will be available on pharmacy shelves in the United Kingdom from late October 2015.

- Mute to go on sale in UK pharmacies from late October 2015

- First step in global pharmacy distribution strategy

- Global sleep assistance market estimated at over US$32 billion

Mute is Rhinomed's over the counter snoring/sleep quality product which has been shown in trials (n=236) carried out in late 2014 to reduce snoring in 75% of participants. It is a discrete device that gently opens the nostrils to improve breathing capacity and reduce snoring. Mute is registered with the USFDA, Australian TGA and European Authority (CE Mark).

"Getting Mute into pharmacies in the UK is an important step for Rhinomed as we seek to expand our global pharmacy distribution footprint. A recent omnibus survey identified that 75% of Britons snore and 30% snore almost every night. Ensuring British snorers can purchase Mute through the high street pharmacy channel is critically important and a significant milestone achievement for the company", said CEO Michael Johnson.

According to IMS Health global spending on sleep related products has increased 8.8% annually since 2008 with the market reaching USD32 billion annually in 2012.

The Mute technology will be sold exclusively in the United Kingdom by Boots UK, the leading pharmacy-led health and beauty retailer.. Full terms, including pricing and minimum order sizes remain confidential. The exclusive distribution deal supersedes previous UK distribution deals for Mute.

About Rhinomed Limited

Rhinomed Limited ASX:RNO

Rhinomed Limited (ASX:RNO) is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise applications of its technology portfolio in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information, go to www.rhinomed.global

TwitterFollow the Turbine on Twitter at @theturbinecom
Follow Mute Snoring on Twitter at @mutesnoring

https://plus.google.com/112881158738803317960 https://twitter.com/rhinomedceo https://www.facebook.com/Rhinomed https://www.youtube.com/channel/UCU_Op9p0A1e4FW5jCPzA2Ww https://www.linkedin.com/company/rhinomed-limited-australia abnnewswire.com 


Contact

Media Enquiries
Michael Johnson
CEO & Managing Director
T: +61 (03) 8416 0900
mjohnson@rhinomed.global



ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 5) (Last 30 Days: 21) (Since Published: 5125)